New work has confirmed calprotectin (which is tested for here at Ascenda BioSciences) in the diagnosis of inflammatory bowel disease (IBD) in pediatric patients, and is a terrific modality to help avoid cumbersome referrals and costly colonoscopies.

A recent study from Kaiser Permanente and Oregon Health & Science University, in Portland, found that the test has superlative sensitivity for detecting IBD, with average levels roughly 16 times higher in children with the disease than in those with even other gastrointestinal problems. This is fantastic news for parents and patients of children who may be facing a diagnosis of IBD.

More information:

Share This